The testosterone-fuelled battle that has softened Acrux's (ASX:ACR) share price took an interesting turn over the weekend

Matthijs Smith

Canaccord Genuity Australia

The testosterone-fuelled battle that has softened Acrux's (ASX:ACR) share price took an interesting turn over the weekend. In January the US FDA issued a Drug Safety Communication (DSC) for testosterone replacement therapies (TRTs) in response to a couple of studies that claimed to show that, in certain groups of men, these therapies could increase the risk of heart attack, stroke and death. This move followed a year of various lobby groups such as Public Citizen clamoring for all TRT's to carry a warning of these risks on the outside of their packets. Last week, a group of 125 researchers and doctors called The Androgen Group wrote to the journal that published one of these studies asking for it to be withdrawn. Why? Well one of the reasons was that it turned out that 10% of the participants were actually women. Oooops! ACR will report sales of Q1 Axiron during April.


MORE ON



Senior Life Sciences Analyst
Canaccord Genuity Australia

PhD Human Genetics, MBA, BSc Hons (1st Class). Sell side analyst specialising in life science companies since 2006. Previous background in biotech companies, medical research, consulting with BCG and scientific journalism with Nature

Expertise

No areas of expertise

I would like to

Only to be used for sending genuine email enquiries to the Contributor. Livewire Markets Pty Ltd reserves its right to take any legal or other appropriate action in relation to misuse of this service.

Personal Information Collection Statement
Your personal information will be passed to the Contributor and/or its authorised service provider to assist the Contributor to contact you about your investment enquiry. They are required not to use your information for any other purpose. Our privacy policy explains how we store personal information and how you may access, correct or complain about the handling of personal information.